دورية أكاديمية
أعرض في EDS

NASH-related increases in plasma bile acid levels depend on insulin resistance.

التفاصيل البيبلوغرافية
العنوان: NASH-related increases in plasma bile acid levels depend on insulin resistance.
المؤلفون: Grzych G; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Chávez-Talavera O; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Descat A; Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France., Thuillier D; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Verrijken A; Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk/Antwerp, Belgium.; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, 2650 Edegem/Antwerp, Belgium., Kouach M; Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France., Legry V; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Verkindt H; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Raverdy V; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Legendre B; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Caiazzo R; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Van Gaal L; Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk/Antwerp, Belgium.; Department of Endocrinology, Diabetology and Metabolism, Antwerp University Hospital, 2650 Edegem/Antwerp, Belgium., Goossens JF; Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France., Paumelle R; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Francque S; Laboratory of Experimental Medicine and Pediatrics, Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk/Antwerp, Belgium.; Department of Gastroenterology and Hepatology, Antwerp University Hospital, 2650, Edegem, Antwerp, Belgium., Pattou F; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1190 - EGID, F-59000, Lille, France., Haas JT; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Tailleux A; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France., Staels B; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011- EGID, F-59000 Lille, France.
المصدر: JHEP reports : innovation in hepatology [JHEP Rep] 2020 Dec 16; Vol. 3 (2), pp. 100222. Date of Electronic Publication: 2020 Dec 16 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101761237 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5559 (Electronic) Linking ISSN: 25895559 NLM ISO Abbreviation: JHEP Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2019]-
مستخلص: Background & Aims: Plasma bile acids (BAs) have been extensively studied as pathophysiological actors in non-alcoholic steatohepatitis (NASH). However, results from clinical studies are often complicated by the association of NASH with type 2 diabetes (T2D), obesity, and insulin resistance (IR). Here, we sought to dissect the relationship between NASH, T2D, and plasma BA levels in a large patient cohort.
Methods: Four groups of patients from the Biological Atlas of Severe Obesity (ABOS) cohort (Clinical Trials number NCT01129297) were included based on the presence or absence of histologically evaluated NASH with or without coincident T2D. Patients were matched for BMI, homeostatic model assessment 2 (HOMA2)-assessed IR, glycated haemoglobin, age, and gender. To study the effect of IR and BMI on the association of plasma BA and NASH, patients from the HEPADIP study were included. In both cohorts, fasting plasma BA concentrations were measured.
Results: Plasma BA concentrations were higher in NASH compared with No-NASH patients both in T2D and NoT2D patients from the ABOS cohort. As we previously reported that plasma BA levels were unaltered in NASH patients of the HEPADIP cohort, we assessed the impact of BMI and IR on the association of NASH and BA on the combined BA datasets. Our results revealed that NASH-associated increases in plasma total cholic acid (CA) concentrations depend on the degree of HOMA2-assessed systemic IR, but not on β-cell function nor on BMI.
Conclusions: Plasma BA concentrations are elevated only in those NASH patients exhibiting pronounced IR.
Lay Summary: Non-alcoholic steatohepatitis (NASH) is a progressive liver disease that frequently occurs in patients with obesity and type 2 diabetes. Reliable markers for the diagnosis of NASH are needed. Plasma bile acids have been proposed as NASH biomarkers. Herein, we found that plasma bile acids are only elevated in patients with NASH when significant insulin resistance is present, limiting their utility as NASH markers.
Competing Interests: The authors declare that they have no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
(© 2021 The Authors.)
التعليقات: Erratum in: JHEP Rep. 2024 May 18;6(6):101097. doi: 10.1016/j.jhepr.2024.101097. (PMID: 38978774)
References: Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. (PMID: 30174213)
Hepatology. 2005 Jun;41(6):1313-21. (PMID: 15915461)
Hepatology. 2018 Jan;67(1):328-357. (PMID: 28714183)
Nat Rev Endocrinol. 2014 Aug;10(8):488-98. (PMID: 24821328)
J Lipid Res. 2010 Apr;51(4):832-42. (PMID: 19965590)
Curr Opin Lipidol. 2019 Jun;30(3):244-254. (PMID: 30893108)
J Hepatol. 2019 Oct;71(4):793-801. (PMID: 31279902)
Metabolism. 2011 Mar;60(3):404-13. (PMID: 20423748)
Medicine (Baltimore). 2016 Mar;95(10):e2778. (PMID: 26962776)
Clin Chem Lab Med. 2019 Jul 26;57(8):1218-1228. (PMID: 30964746)
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9. (PMID: 20042775)
Annu Rev Physiol. 2016;78:181-205. (PMID: 26667070)
Ann Clin Biochem. 2013 Jul;50(Pt 4):360-4. (PMID: 23771134)
Gastroenterology. 2013 Sep;145(3):574-82.e1. (PMID: 23727264)
Nutr Metab (Lond). 2010 Sep 03;7:73. (PMID: 20815878)
Dig Dis Sci. 2015 Nov;60(11):3318-28. (PMID: 26138654)
Gut. 2018 Oct;67(10):1881-1891. (PMID: 28774887)
Gut. 2020 Mar;69(3):564-568. (PMID: 31366455)
Diabetes. 2015 Apr;64(4):1168-79. (PMID: 25338812)
J Hepatol. 2020 Sep;73(3):505-515. (PMID: 32298765)
Ann Surg. 2014 Nov;260(5):893-8; discussion 898-9. (PMID: 25379859)
Lancet. 2019 Dec 14;394(10215):2184-2196. (PMID: 31813633)
Gastroenterology. 2017 May;152(7):1679-1694.e3. (PMID: 28214524)
Metabolism. 2020 Feb;103:154042. (PMID: 31785259)
Gastroenterology. 2020 May;158(7):1999-2014.e1. (PMID: 32044314)
J Hepatol. 2016 Jun;64(6):1388-402. (PMID: 27062661)
BMC Med Genomics. 2019 Jun 3;12(1):80. (PMID: 31159817)
Front Neurosci. 2015 Jun 03;9:199. (PMID: 26089773)
J Clin Endocrinol Metab. 2017 Oct 1;102(10):3783-3794. (PMID: 28938455)
Diabetes. 2004 Apr;53(4):890-8. (PMID: 15047603)
Ann Surg. 2016 Nov;264(5):878-885. (PMID: 27560624)
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. (PMID: 30559228)
Hepatology. 2018 Feb;67(2):534-548. (PMID: 28696585)
Lancet. 2015 Mar 14;385(9972):956-65. (PMID: 25468160)
Diabetes Care. 1998 Dec;21(12):2191-2. (PMID: 9839117)
J Clin Endocrinol Metab. 2016 Aug;101(8):3002-9. (PMID: 27270475)
فهرسة مساهمة: Keywords: ABOS, Biological Atlas of Severe Obesity*; ADA, American Diabetes Association*; BA, bile acids*; Bile acids*; C4, 7alpha-hydroxy-4-cholesten-3-one*; CA, cholic acid*; CDCA, chenodeoxycholic acid*; DCA, deoxycholic acid*; Diabetes*; FPG, fasting plasma glycaemia*; FXR, farnesoid-X-receptor*; GCA, glycocholic acid*; GCDCA, glycochenodeoxycholic acid*; GDCA, glycodeoxycholic acid*; GHCA, glycohyocholic acid*; GHDCA, glycohyodeoxycholic acid*; GLCA, glycolithocholic acid*; GUDCA, glycoursodeoxycholic acid*; HCA, hyocholic acid*; HDCA, hyodeoxycholic acid*; HOMA2, homeostatic model assessment 2*; HbA1c, glycated haemoglobin*; IR, insulin resistance*; Insulin resistance*; LCA, lithocholic acid*; MAFLD, metabolic associated fatty liver disease*; NAFL, non-alcoholic fatty liver*; NAFLD*; NAFLD, non-alcoholic fatty liver disease*; NASH*; NASH, non-alcoholic steatohepatitis*; OGTT, oral glucose tolerance test*; Obesity*; T2D, type 2 diabetes*; TCA, taurocholic acid*; TCDCA, taurochenodeoxycholic acid*; TDCA, taurodeoxycholic acid*; THCA, taurohyocholic acid*; THDCA, taurohyodeoxycholic acid*; TLCA, taurolithocholic acid*; TUDCA, tauroursodeoxycholic acid*; Translational study*; UDCA, ursodeoxycholic acid*
تواريخ الأحداث: Date Created: 20210222 Latest Revision: 20240709
رمز التحديث: 20240709
مُعرف محوري في PubMed: PMC7878982
DOI: 10.1016/j.jhepr.2020.100222
PMID: 33615207
قاعدة البيانات: MEDLINE
الوصف
تدمد:2589-5559
DOI:10.1016/j.jhepr.2020.100222